Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Anderson

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
Oncology (Williston Park, N.Y.)|June 4, 2010
Tailoring treatment for multiple myeloma patients with relapsed and refractory diseasePaul G Richardson, Jacob Laubach, Constantine Mitsiades, et al.
Transfusion|November 9, 2002
Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donorsKaren K Ballen, Julie Hicks, Bernie Dharan, et al.
Nature Reviews. Clinical Oncology|October 3, 2018
Accelerating anticancer drug development - opportunities and trade-offsSharyl J Nass, Mace L Rothenberg, Rebecca Pentz, et al.
The European Respiratory Journal|September 17, 2013
Randomised controlled trial of azithromycin in smokers with asthmaEuan J Cameron, Rekha Chaudhuri, Frances Mair, et al.
Angewandte Chemie (International Ed. in English)|January 20, 2026
Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein DegradationChen Song, Qi Liu, Tingjian Wang, et al.
The Lancet. Haematology|March 28, 2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 studyPaul G Richardson, Sara Bringhen, Peter Voorhees, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Molecular Biology of the Cell|August 9, 2013
Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular fluxMary M Buschmann, Le Shen, Harsha Rajapakse, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
Oncology (Williston Park, N.Y.)|June 4, 2010
Tailoring treatment for multiple myeloma patients with relapsed and refractory diseasePaul G Richardson, Jacob Laubach, Constantine Mitsiades, et al.
Transfusion|November 9, 2002
Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donorsKaren K Ballen, Julie Hicks, Bernie Dharan, et al.
Nature Reviews. Clinical Oncology|October 3, 2018
Accelerating anticancer drug development - opportunities and trade-offsSharyl J Nass, Mace L Rothenberg, Rebecca Pentz, et al.
The European Respiratory Journal|September 17, 2013
Randomised controlled trial of azithromycin in smokers with asthmaEuan J Cameron, Rekha Chaudhuri, Frances Mair, et al.
Angewandte Chemie (International Ed. in English)|January 20, 2026
Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein DegradationChen Song, Qi Liu, Tingjian Wang, et al.
The Lancet. Haematology|March 28, 2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 studyPaul G Richardson, Sara Bringhen, Peter Voorhees, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Molecular Biology of the Cell|August 9, 2013
Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular fluxMary M Buschmann, Le Shen, Harsha Rajapakse, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Pageof 11